Production (Stage)
Haemonetics Corporation
HAE
$66.06
-$0.10-0.15%
NYSE
| 03/29/2025 | 12/28/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -5.15% | 0.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -5.15% | 0.88% | |||
| Cost of Revenue | -11.57% | -3.68% | |||
| Gross Profit | -0.38% | 4.56% | |||
| SG&A Expenses | 10.36% | 0.98% | |||
| Depreciation & Amortization | -7.64% | -0.28% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -3.08% | -1.87% | |||
| Operating Income | -13.99% | 14.59% | |||
| Income Before Tax | 41.71% | 11.66% | |||
| Income Tax Expenses | 2.68% | 14.26% | |||
| Earnings from Continuing Operations | 54.64% | 10.83% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 54.64% | 10.83% | |||
| EBIT | -13.99% | 14.59% | |||
| EBITDA | -17.62% | 9.47% | |||
| EPS Basic | 58.07% | 12.17% | |||
| Normalized Basic EPS | -21.68% | 13.80% | |||
| EPS Diluted | 59.27% | 12.12% | |||
| Normalized Diluted EPS | -21.59% | 13.76% | |||
| Average Basic Shares Outstanding | -2.17% | -1.20% | |||
| Average Diluted Shares Outstanding | -2.30% | -1.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||